Price Change to Note: What’s Propelling Imprimis Pharmaceuticals Inc to Decline So Much?

Price Change to Note: What's Propelling Imprimis Pharmaceuticals Inc to Decline So Much?

The stock of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) is a huge mover today! About 65,839 shares traded hands. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has declined 28.75% since April 13, 2016 and is downtrending. It has underperformed by 32.68% the S&P500.
The move comes after 6 months negative chart setup for the $34.71 million company. It was reported on Nov, 15 by Barchart.com. We have $2.12 PT which if reached, will make NASDAQ:IMMY worth $4.86 million less.

According to Zacks Investment Research, “Imprimis Pharmaceuticals, Inc. is a pharmaceutical company focused on its proprietary ophthalmology and urology drug formulations. Imprimis recently launched its urology business, which includes a patented formulation to address patients suffering from interstitial cystitis.”

Insitutional Activity: The institutional sentiment increased to 1.2 in Q2 2016. Its up 0.06, from 1.14 in 2016Q1. The ratio improved, as 3 funds sold all Imprimis Pharmaceuticals Inc shares owned while 2 reduced positions. 1 funds bought stakes while 5 increased positions. They now own 1.66 million shares or 37.14% less from 2.64 million shares in 2016Q1.
Blackrock Fund Advsrs reported 32,979 shares or 0% of all its holdings. Bard Assocs holds 0.13% or 65,500 shares in its portfolio. Pnc Financial holds 2,000 shares or 0% of its portfolio. Opaleye, a Massachusetts-based fund reported 265,000 shares. Moreover, Creative Planning has 0% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 750 shares. Berson And Corrado Invest Advsr Ltd Liability Corp owns 31,107 shares or 0.08% of their US portfolio. Blackrock Investment Mgmt Limited Com holds 0% of its portfolio in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 1,966 shares. Manufacturers Life Insur Com The accumulated 0% or 169 shares. Tower Cap Ltd Com (Trc) last reported 548 shares in the company. Moreover, Marathon Capital has 0.05% invested in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) for 25,000 shares. The California-based Granite Invest Prns Ltd Liability has invested 0.05% in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY). Marathon Asset Lp has 0.17% invested in the company for 833,333 shares. Bankshares Of America De holds 0% or 17,797 shares in its portfolio. Vanguard Gru Incorporated owns 168,584 shares or 0% of their US portfolio. The Illinois-based Northern Corporation has invested 0% in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY).

More important recent Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) news were published by: Prnewswire.com which released: “Imprimis Pharmaceuticals Strengthens Senior Leadership Team with Key Hires in …” on August 15, 2016, also Prnewswire.com published article titled: “Imprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the …”, Prnewswire.com published: “Imprimis Pharmaceuticals Registers its New Jersey Facility with the FDA as an …” on October 28, 2016. More interesting news about Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) was released by: Prnewswire.com and their article: “Imprimis Pharmaceuticals Announces Preliminary Revenue for Third Quarter 2015” with publication date: October 20, 2015.

IMMY Company Profile

Imprimis Pharmaceuticals, Inc. (Imprimis), incorporated on January 11, 2006, is engaged in the development, production and dispensing of compounded pharmaceuticals. The Firm operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Firm is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Firm also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment